Second allogeneic hematopoietic stem cell transplantation in patients with acute leukemia relapsed after allogeneic hematopoietic stem cell transplantation

The prognosis of patients with acute leukemia relapsed after allogeneic hematopoietic stem cell transplantation (HSCT) is dismal. We aimed to evaluate the outcomes and prognostic factors of the second HSCT (HSCT2) in acute leukemia patients relapsed after the first HSCT (HSCT1). We analyzed 80 patients who received HSCT2 for relapsed acute leukemia in two Korean institutes. All but four patients received HSCT2 from a donor other than matched sibling donor: an unrelated donor (URD) in 30 and a familial haploidentical donor (FHD) in 46. Forty‐four patients (55.0%) were in complete remission (CR) or CR with incomplete count recovery (CRi) at HSCT2, and the median time from HSCT1 to relapse was 9 months. The 2‐year overall survival (OS) and event‐free survival (EFS) were 21.0% and 17.5%, respectively. The outcomes were similar between URD and FHD. Multivariate analysis demonstrated that disease status (active disease vs. CR/CRi) at HSCT2 and remission duration after HSCT1 were independent prognostic factors for OS and EFS after HSCT2. HSCT2 from URD or FHD was feasible in patients with acute leukemia relapsed after allogeneic HSCT. Also, our study confirmed two critical prognostic factors; disease status at HSCT2 and remission duration after HSCT1.

[1]  N. Kröger,et al.  Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT , 2019, Blood Cancer Journal.

[2]  R. Storb,et al.  Second allogeneic hematopoietic cell transplantation for relapse after first allografts , 2019, Leukemia & lymphoma.

[3]  M. Labopin,et al.  Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse , 2018, JAMA oncology.

[4]  J. Sierra,et al.  Analysis of relapse after transplantation in acute leukemia: A comparative on second allogeneic hematopoietic cell transplantation and donor lymphocyte infusions. , 2018, Experimental hematology.

[5]  J. Lipton,et al.  Outcome following second allogeneic hematopoietic cell transplantation: A single‐center experience , 2018, European journal of haematology.

[6]  Brian S. Iglehart,et al.  Major Histocompatibility Mismatch and Donor Choice for Second Allogeneic Bone Marrow Transplantation. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  F. Appelbaum,et al.  Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[8]  I. Aldoss,et al.  Outcome of Second Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Lymphoblastic Leukemia. , 2016, Clinical Lymphoma, Myeloma & Leukemia.

[9]  J. Sierra,et al.  Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Español de Trasplante Hematopoyetico. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[10]  J. Gribben,et al.  Second reduced intensity conditioning allogeneic transplant as a rescue strategy for acute leukaemia patients who relapse after an initial RIC allogeneic transplantation: analysis of risk factors and treatment outcomes , 2016, Bone Marrow Transplantation.

[11]  M. Arat,et al.  The use of second allogeneic hematopoietic stem cell transplantation for hematologic malignancies relapsed after the first: Does it worth to do? , 2016, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[12]  N. Kröger,et al.  Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  E. Shpall,et al.  Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia , 2013, Bone Marrow Transplantation.

[14]  N. Kröger,et al.  Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. , 2012, Blood.

[15]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[16]  A. Cherry,et al.  Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. , 2005, Blood.

[17]  E. Estey,et al.  Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia , 2005, Bone Marrow Transplantation.

[18]  S. Asano,et al.  Second Allogeneic Hematopoietic Stem Cell Transplantation for Leukemia Relapse After First Allogeneic Transplantation: Outcome of 16 Patients in a Single Institution , 2002, International journal of hematology.

[19]  M. Labopin,et al.  Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Kiehl,et al.  Second allogeneic hematopoietic stem cell transplantation as treatment for leukemia relapsing following a first transplant , 2000, Bone Marrow Transplantation.

[21]  M. Horowitz,et al.  Second HLA-identical sibling transplants for leukemia recurrence. , 1992, Bone marrow transplantation.

[22]  C. Bloomfield,et al.  Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.